Edition:
United States

People: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3.48USD
26 May 2017
Change (% chg)

$-0.21 (-5.69%)
Prev Close
$3.69
Open
$3.60
Day's High
$3.63
Day's Low
$3.48
Volume
7,683,160
Avg. Vol
6,337,624
52-wk High
$7.15
52-wk Low
$3.35

Spigelman, Melvin 

Dr. Melvin K. Spigelman is an Independent Director of the Company. He served as a director of our Company since August 2008. Since January 2009, Dr. Spigelman has served as President and CEO and from June 2003 to December 2008 as Director of Research and Development for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. Dr. Spigelman was President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001, Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma, and from 1992 to 2000, Dr. Spigelman was the Vice President of Research and Development at Knoll. Dr. Spigelman has been a director of The Medicines Company since September 2005. Dr. Spigelman received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine. Dr. Spigelman’s expertise in drug development and management qualifies him to serve as a director of our company.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gary Jacob

4,211,680

Gary Gemignani

--

Marino Garcia

--

Patrick Griffin

1,195,750

Troy Hamilton

1,362,920

Bernard Denoyer

707,434
As Of  30 Dec 2015